Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 11/20 | 0.61 |
| ▸ | ADH1C | P00326 | 8/20 | 0.61 |
| ▸ | ADH4 | P08319 | 2/20 | 0.47 |
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4579032 | 0.93 | — | — | |
| SCHEMBL3955780 | 0.84 | ADH1A (0.44) | ADH1AADH1CADH4 | |
| SCHEMBL8383244 | 0.77 | ADH1A (0.96) | ADH1AADH1CADH4ADH1B | |
| SCHEMBL7802361 | 0.76 | ADH1A (1.00) | ADH1AADH1CADH4ADH1B | |
| SCHEMBL9661004 | 0.74 | ADH1A (1.00) | ADH1AADH1CADH4ADH1B | |
| SCHEMBL6984253 | 0.74 | ADH1A (1.00) | ADH1AADH1CADH4ADH1B | |
| Hydrochloric Acid SCHEMBL8303801 | 0.74 | ADH1A (0.96) | ADH1AADH1CADH4ADH1B | |
| SCHEMBL9660553 | 0.74 | ADH1A (1.00) | ADH1AADH1CADH4ADH1B | |
| SCHEMBL7251997 | 0.74 | ADH1A (0.66) | ADH1AADH1CADH4ADH1B | |
| SCHEMBL27722465 | 0.74 | ADH1A (0.59) | ADH1AADH1CADH4ADH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059941-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B] PYRIDINE/PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | claimed |
| EP-1891069-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B]PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | claimed |
| WO-2006125958-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4 , 5B] PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | claimed |
| US-20110059941-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B] PYRIDINE/PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2011-03-10 | — | — | US | disclosed |
| EP-1891069-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B]PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006125958-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4 , 5B] PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059941-A1 | 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B] PYRIDINE/PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS | GCK, PDXK, GCKR | ADH1A 1896/4885ADH1C 1247/4885ADH4 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.